Delivered-To: pgepnewsletter@gmail.com
Received: by 2002:a98:c004:0:b0:1eb:e128:bbe3 with SMTP id l4csp3966198eic;
        Mon, 15 Jan 2024 14:41:18 -0800 (PST)
X-Google-Smtp-Source: AGHT+IFYqL6/FSJve0dETzl1o/vyy8+dxcgchtS896BWrwIxAezddgbYfS3e8sqXiG+Ek+cUM0VB
X-Received: by 2002:a05:620a:388:b0:783:3514:63b4 with SMTP id q8-20020a05620a038800b00783351463b4mr7417925qkm.113.1705358477788;
        Mon, 15 Jan 2024 14:41:17 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1705358477; cv=none;
        d=google.com; s=arc-20160816;
        b=bxSLdiv+wa00sXvi2+FB4RJhExQAvJed/MD8lga239W3k6QP8/VfFJ3BmraqxzSJA+
         tnOhpQ9KpmNprLs0S62IdgpsqXdTB/7vWF/z3+df7Lc6PLZnFERLvrd6AtYllZqX90b5
         N501Zo9iZqVkyVK4/h5vd/8KbHO/NZT1Z+LDaEzK9wXx0A/1YmvnbnJwU4MaWh0A3F9a
         Mc49axBLdflILQIGv5c6uAha7ZdBGz00SAaBdajZ5kHagkBEETBCwpebw2Qu4ZBJA2v/
         3daDNqXlzLNEiLXmvhy3ZO0/wuOM91mH4Uwe1GXvrwPGkfoIIkmSUdk3WP922IFih/Lh
         uLbg==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=list-unsubscribe:to:reply-to:subject:message-id:mime-version:from
         :date:dkim-signature:dkim-signature;
        bh=VIK2RsfZqWykNjH8X67ttsBO3nTsZEvmFT6a+lGd3uE=;
        fh=m8+yFGL9AGrkSifADXzxzWHypeMVd9MF7/kbikeN2H4=;
        b=Qcitv8ckrCdPie/ywu3Saja6SNp9/QukcdrZgCUpO5RuTouhzxlbYotJPyF01YSPNl
         4t5q4dRCYkCD+AFkg8CD/kcifpW8Hr+Rj46JDk2o7FrGpc5PPw8hzdo7ot9swJ3UGBCX
         xgR9rU7r7gYexG/F0EktKLU69bkF4hhZncndzWT7YpJZALT4RCBLt6S2OX2QuRledgHP
         4zmPlGQzkvk5T7Az2nydfn5Ca69/b1yPLFLDxE/H3HpZPlrUJ3PVEI0rZ1ulihjBEA/N
         v3L84z/N7D/Mf3+G6R0zyIZ6BDLwplaXHy9ZjLix7OT4jwgtV2YIjgtsv9C3YoqNLAhF
         eYnw==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=IgFr1qT+;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=Z79sKmsS;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
Return-Path: <bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org>
Received: from xtrwrkzn.outbound-mail.sendgrid.net (xtrwrkzn.outbound-mail.sendgrid.net. [167.89.81.226])
        by mx.google.com with ESMTPS id f10-20020a05620a12ea00b0078327d5a20bsi8616947qkl.785.2024.01.15.14.41.17
        for <pgepnewsletter@gmail.com>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Mon, 15 Jan 2024 14:41:17 -0800 (PST)
Received-SPF: pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) client-ip=167.89.81.226;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=IgFr1qT+;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=Z79sKmsS;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=isid.org;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=s1; bh=VIK2RsfZqWykNjH8X67ttsBO3nTsZEvmFT6a+lGd3uE=;
	b=IgFr1qT+hj7MdyMNgHHpIt2ItUg8ypQpWcP5XV9n13cVSX2uTypacbV5L3fg9WLf+iqW
	9YYXD0BD9ycUyc3tRNqGPqP0f7A3cDgAEi3q55Pq4lnP5dn2IkoiKJhWeBig1AYD90WS8I
	DitTUIL4UymcE0lDyT/JYiqzuIKevavIdiGoEpCfstnhh7ZY0szCuVnTZgFzpLEqloVM6N
	dECZ2WO2QWFu4/T/zSd2Bd4JKuQLBN4eOna6eFeIANiUcARDxoOxKdvNaRUNElVsZx7dqR
	e4sloqmv/2Bkwx44c/Cae1iDlGfO5gOq/wgLhWCaXoKvpZ0+jMW3kVHMVDpSGeUQ==
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=smtpapi; bh=VIK2RsfZqWykNjH8X67ttsBO3nTsZEvmFT6a+lGd3uE=;
	b=Z79sKmsSBbcQ71GfUyKphVZOfBUc8BMNiPCPc82yyRZcUMecvoJRpQQjRgLN0URDfIJV
	HsXe4STPrWKMAOLenzH71Z1oDKV8CEFByxRSVltob1LQvDrGZv3xK6X/m24HJzrQt/b3uX
	MshAOXVveAo1Ovgn4DENsnmpAPkxmb/2E=
Received: by filterdrecv-59494cb4-9jxdw with SMTP id filterdrecv-59494cb4-9jxdw-1-65A5B48A-2A
        2024-01-15 22:41:14.985518838 +0000 UTC m=+7790403.614369212
Received: from MTkyNjg2NjI (unknown)
	by geopod-ismtpd-20 (SG) with HTTP
	id pdEtPQL7STm5gmEwSQGkkg
	Mon, 15 Jan 2024 22:41:14.802 +0000 (UTC)
Content-Type: multipart/alternative; boundary=e074754f5a76ce6dcaa5930a94219a84b9d96e28e675a95f2048e4271d85
Date: Mon, 15 Jan 2024 22:41:16 +0000 (UTC)
From: ProMED <promed@isid.org>
Mime-Version: 1.0
Message-ID: <pdEtPQL7STm5gmEwSQGkkg@geopod-ismtpd-20>
Subject: PRO/AH/EDR> Meningitis, meningococcal - Nigeria: update
Reply-To: noreply@isid.org
X-Feedback-ID: 19268662:SG
X-SG-EID: 
 =?us-ascii?Q?lYKUi1ucKQwcfoVB1xAcbBSlsJP9QSi7ed2VWI0p5NjpCc5BQK+kujBGGO1mU1?=
 =?us-ascii?Q?iBPmFT5t0lkwpBV9SsuESSbQX++BwSZlE0JkS0M?=
 =?us-ascii?Q?cwZNzFHS0nk5yMxOuK4inkbKMAxVQIw4C1DQ279?=
 =?us-ascii?Q?7gZDDEtgYZANevMRXXeS5fsAMIPYPHsdbYnUr3W?=
 =?us-ascii?Q?A5vMhko+Bau6Ov=2FVfRWJkTTZsTdkH8FxVvhHa1J?=
 =?us-ascii?Q?Ag9EGVjkIYZpH5XqLcDeLSY0f1Yz=2FYwfYK0bC9?=
X-SG-ID: 
 =?us-ascii?Q?se=2F49CGmbS0sfR97ImeXvNhg9p9jggtUUChgqoY2wUiShGf=2FO8XJWpH34Od4Nd?=
 =?us-ascii?Q?fxXa6jil96uRcJkF+N+LeVnO1tx80ddOyoyOo=2Fc?=
 =?us-ascii?Q?Brxcl3ERAm0cOY743=2FFH59DWiSf5OzXORh1DLKt?=
 =?us-ascii?Q?hb1NMKty3PsA5ju0ZzxCrq1WQuZSEQf=2FJlWtgqv?=
 =?us-ascii?Q?cZmsyCHlNUZsDC3xN0lWR67T2PsHK2VnJuPThpH?=
 =?us-ascii?Q?fnEU6myVQVrOrqT3m5+sprhLQazC41BN64IaM3a?=
 =?us-ascii?Q?Ar6z0xVBRwYKSAvHkT9Fa1fDTYIp7J1VZ=2FucsyC?=
 =?us-ascii?Q?Ocbkh3VS55Sjj8YKInSx6bvdOAfjVLwWQcB+g9T?=
 =?us-ascii?Q?8e9TQ+vctQgTagaiH=2FC6TKGWcclV9Eh09Sej7fi?=
 =?us-ascii?Q?ds45GfrnR5tTOoS8zk+HIc3nA=2FAVGVK0gjRR0av?=
 =?us-ascii?Q?7acAdUQ+VkJ+4SLbkJdvjccfXTrn1l1agC5jcWh?=
 =?us-ascii?Q?RdYqfaCkKBYhfLbq6UHjeJGTtx1adplEuKVo861?=
 =?us-ascii?Q?m9SFMC3NfUONTrCuTNpV5lJOY+k+t5uL6AJkMjj?=
 =?us-ascii?Q?Sq1h1dqIZ6SNpvXZ3q+WI33fUP2YctdnBOBlGEj?=
 =?us-ascii?Q?sScoVbMu9SIEoMpx=2FS+=2FVC=2Fa5eugutkMd2FaevH?=
 =?us-ascii?Q?qJwZYkJfg=2FWDKdcD5+vQaJ3ljWU3ZNW=2FkCSbgUP?=
 =?us-ascii?Q?25wWkBnJCwQ8lFp6mjPIdhNyk0v7SZlT9yP0LOR?=
 =?us-ascii?Q?XLK58Mj5UosMT8rl8ZOdKLrUxyuEHNnCUkX3HVv?=
 =?us-ascii?Q?qXSMeMioXzVEt8XDhjq6Lslf7EdJD3Se=2F+MYWHM?=
 =?us-ascii?Q?mYNZcbz6GVDpqUC5MLqOhc5u5A=3D=3D?=
To: pgepnewsletter@gmail.com
X-Entity-ID: 3CKJgmVGbBVD214dsRqreg==
List-Unsubscribe: 
 =?us-ascii?Q?=3Cmailto=3Aunsubscribe=40em7004=2Eisid=2Eorg=3Fsubject=3D19268662=2EePAh3BL3C?=
 =?us-ascii?Q?VS0U1qvinViMf3VsxzQ6BYVzfMI0DoeNeJoMDAw?=
 =?us-ascii?Q?dTAwMDrEusDVM0Xag-sfsF1Q=5FR9AWhA=5FJx69ELH?=
 =?us-ascii?Q?-vS4uTAZdUIEVfxUe72Qs-2GCR-U0RbypxCy7kz?=
 =?us-ascii?Q?OBe48IYtVn5M=5FtivE64lar63J9D9QqJ7BUGe8Yt?=
 =?us-ascii?Q?hS6Hd5MJHDko962Ag=3D=3D=2EeJrYSleZ6YziJVF7xNe?=
 =?us-ascii?Q?=5FwG0FXbw-mT49WjTr9ExDiOdoMDAwdTAwMEvqHF?=
 =?us-ascii?Q?mwKR2dCbrePsp9Sx2h-207SRjU0gtkph1WQTBFd?=
 =?us-ascii?Q?ElwjJ6-7Kh-yMJUGnADf8d62II9kXcpTJAGHkMX?=
 =?us-ascii?Q?L0srgk-8MeNij16Ux8v5NAywzLEj=5FaDSDAxMWtN?=
 =?us-ascii?Q?NMegtvo8f4EmAF-NvqXPduYD3TjUTYWrQtvHcb3?=
 =?us-ascii?Q?Y2EjbvAXSX=5FuaF1HyeqeXy79h=5FyF1v7WEy2pc8=5F?=
 =?us-ascii?Q?ExDTd=5FrIzx49fAudMFuv3mSkUIIyVmLyUCFaOzJ?=
 =?us-ascii?Q?7SpB9LGSwn-u9RSjkbODpcFdh-cFuHR1yaJUy0s?=
 =?us-ascii?Q?ZgX4vnzNFFU8dTyphktXfPAk9fFfJ7rBTFNbp2V?=
 =?us-ascii?Q?zZASSxDv539GBUnhrKcNxfW36gaZFyVk7IOYQ5R?=
 =?us-ascii?Q?VjRpss0Q9rIR7t9yAIMhv5g=5FEJfxx21kzGz0z7D?=
 =?us-ascii?Q?IN46bWD2vqsW2WgCx4wUQolEXStTLjvcIllxS4k?=
 =?us-ascii?Q?x03lxlxZYNgp7xqbYihuYPYK9IR7eFaPAi2bECp?=
 =?us-ascii?Q?L06xu5rzDUjr=5F8kOJJv-8kag8wrZffPwMrR4fFe?=
 =?us-ascii?Q?J5j-31QmhLdcyM=5FxYbfaQita2RRPTJgzB-fwqxz?=
 =?us-ascii?Q?L-6Cbps7Gu=5FEyzRrv9aB4RPvx89qV1Ge5xZfoCz?=
 =?us-ascii?Q?o7gCEbPhMwR6VbYCDeRooPGsCJMRrSxNHVLaHnr?=
 =?us-ascii?Q?sBPmgvI4cJnH9iIfjpRvoK6iPym3cnsXWEsDaY5?=
 =?us-ascii?Q?mmy0ezDJNgARko1KpRS0m1JPbPzKfpqPpDg7uKE?=
 =?us-ascii?Q?qB9E9bFNnc3SdrhcvJpVT2Mx2RAsNKjMuM-IWkS?=
 =?us-ascii?Q?nQY3zm33A4huFXohegJFCjcyqOoSEyRRnVKZlUW?=
 =?us-ascii?Q?MmoXrWq7MWAPSRiCSlTlZ3t2ufWqWlvSqlqIyLA?=
 =?us-ascii?Q?AUlJ6fAjsOF9Jx8DGifH4qXlAjh0vm8kjxAwF3G?=
 =?us-ascii?Q?dlFlfZ0kF3hfNKvtbldwuFbsbTUDtwn=5F4Ia6FB1?=
 =?us-ascii?Q?3GmBbMrK16cfqdED5wzPFukerDMRUcy0PLcY1xG?=
 =?us-ascii?Q?iA3CgBTEsEK3W7mGG1Il3XQ3=5FsLNuLKyYHBjK=5Fs?=
 =?us-ascii?Q?Rg8dL8wGs1Si0dXRuZ807T7LBFeNKefgM9dPqFP?=
 =?us-ascii?Q?8JILNA=3D=3D=3E?=

--e074754f5a76ce6dcaa5930a94219a84b9d96e28e675a95f2048e4271d85
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain; charset=us-ascii
Mime-Version: 1.0

MENINGITIS, MENINGOCOCCAL - NIGERIA: UPDATE
*******************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Thu 11 Jan 2024
Source: Premium Times [edited]
<https://www.premiumtimesng.com/news/top-news/657924-meningitis-kills-190-i=
n-nigeria-in-two-years-ncdc.html>


Between 2022 and 2023, Nigeria recorded a total of 303 confirmed cases
and 190 deaths from cerebrospinal meningitis (CSM) across 29 states
and the Federal Capital Territory (FCT).

CSM occurs when there is an acute inflammation of the membranes
covering the brain and the spinal cord.

According to a public health advisory released Thursday [11 Jan 2024]
by the Nigeria Centre for Disease Control (NCDC), 2765 suspected cases
of CSM were also recorded across 140 local government areas (LGAs) in
the affected 29 states and FCT.

NCDC noted that the highest burden of CSM in Nigeria occurs in the
"Meningitis Belt," which includes all 19 states in the Northern
region, the FCT, and some southern states such as Bayelsa, Cross
River, Delta, Ekiti, Ogun, Ondo, and Osun.

The disease control centre explained that CSM is an epidemic-prone
disease with cases reported all year round in Nigeria. It added that
weather conditions like the dry season with dust, winds, cold nights,
and frequent upper respiratory tract infections increase the risk of
infection.

The report shows that the 5-14-year-old age group was the most
affected, and 54% of the total suspected cases were males.

Response
--------
NCDC said it is working to prevent, detect, and respond to cases of
CSM in collaboration with the Federal Government of Nigeria through
the Federal Ministry of Health and Social Welfare.

Despite significant progress in surveillance, diagnostic capacity, and
vaccination over the last few years, NCDC noted that CSM remains a
priority disease and a public health threat in Nigeria with annual
outbreaks in high-burden states.

NCDC also highlighted strategies implemented to ensure enhanced
coordination, collaboration, and communication for CSM response in
Nigeria in collaboration with MDAs and partners through the National
CSM Technical Working Group (TWG).

"At the beginning of the season, all state governments and public
health authorities were alerted to the heightened risk of a CSM
outbreak and the need for resource mobilisation for preparedness and
response activities," NCDC noted.

It added that they hold routine meetings of the National
Multi-sectoral CSM TWG to coordinate prevention and preparedness
activities, and regular communication with high-burden states towards
ascertaining status, progress, and challenges.

About meningitis
----------------
According to NCDC, meningitis is an inflammation of the meninges, a
thin layer of the connective tissue that covers the brain and the
spinal cord.

This inflammation can be caused by infection with organisms like
bacteria, viruses, parasites, or fungi. Injuries and certain drugs can
also cause such inflammation.

On transmission, NCDC said meningitis is transmitted from direct
person-to-person contact, including droplets from the nose and throat
of infected persons, and close and prolonged contact with an infected
individual.

"CSM initially presents as fever, headache, nausea and vomiting,
photophobia (pain on looking at bright lights), neck stiffness, and
altered conscious levels. It may be more difficult to observe these
signs in younger children, but irritability, poor feeding, and
inactivity are common," NCDC noted.

NCDC advised that people ensure they receive the appropriate
vaccination required to protect against meningitis.

[Byline: Mariam Ileyemi]

--
Communicated by:
ProMED
via
ProMED-EAFR

[According to the US CDC, meningococcal disease occurs worldwide, with
the highest incidence of disease found in the "meningitis belt" of
sub-Saharan Africa. In this region, major epidemics occur every 5 to
12 years with attack rates reaching 1000 cases per 100 000 population.
The meningitis belt stretches from Senegal to Ethiopia. Most of
Northern Nigeria lies within the meningitis belt. Experts opine the
reported 190 deaths from 2022 to 2023 in Nigeria may be the tip of the
iceberg due to poor reporting especially from rural areas and private
health facilities. Vaccination campaigns are key to raising herd
immunity and preventing outbreaks of meningococcal meningitis. -
Mod.AA

ProMED map of Nigeria:
<https://promedmail.org/promed-post?place=3D8714222,62>]

[See Also:
2023
----
Meningitis, meningococcal - Niger (03): fatal, Africa CDC
http://promedmail.org/post/20230807.8711607
Meningitis, meningococcal - Niger (02): fatal, sg C, mass vacc, ACW
polysac vacc WHO http://promedmail.org/post/20230419.8709577
Meningitis, meningococcal - Niger: fatal, sg C, mass vacc., ACW
polysac. vacc. WHO http://promedmail.org/post/20230209.8708257
Meningitis - Nigeria: (JI) fatal, alert, RFI
http://promedmail.org/post/20230125.8707967
2022
----
Meningitis, meningococcal - Nigeria: (JI) susp, fatal, children, RFI
http://promedmail.org/post/20220611.8703809
2019
----
Meningitis, meningococcal - Niger (02): counterfeit vaccines, alert
http://promedmail.org/post/20190401.6398266
Meningitis, meningococcal - Niger: counterfeit vaccine
http://promedmail.org/post/20190317.6372003
2017
----
Meningitis, meningococcal - Niger: fatal
http://promedmail.org/post/20170519.5048548
2016
----
Meningitis, meningococcal - Niger: fatal
http://promedmail.org/post/20160331.4130594
2015
----
Meningitis, meningococcal - Niger (05): serogroup C, fatal, vaccine
shortage http://promedmail.org/post/20150802.3552463
Meningitis, meningococcal - Niger (04): serogroup C, fatal, WHO,
update http://promedmail.org/post/20150724.3533998
Meningitis, meningococcal - Niger (03): serogroup C, fatal, WHO,
update http://promedmail.org/post/20150517.3368315
Meningitis, meningococcal - Niger (02): fatal, update
http://promedmail.org/post/20150506.3344024
Meningitis, meningococcal - Niger: fatal, serogroups C, W
http://promedmail.org/post/20150430.3332448]
.................................................aa/may/ya/tw/jh
*##########################################################*
************************************************************
ProMED makes every effort to verify the reports that are posted, but the ac=
curacy
and completeness of the information, and of any statements or opinions base=
d
thereon, are not guaranteed. The reader assumes all risks in using informat=
ion
posted or archived by ProMED. ISID and its associated service providers sha=
ll not
be held responsible for errors or omissions or held liable for any damages =
incurred
as a result of use or reliance upon posted or archived material.
************************************************************
Donate to ProMED. Details available at: https://isid.networkforgood.com/pro=
jects/79924-invest-in-the-mission.
************************************************************
Visit ProMED's website at https://www.promedmail.org/.
Submit all items for posting via the ProMED website at https://promedmail.o=
rg/submitinfo/.
If you have any questions or need support, please contact us via the ProMED=
 website at  https://promedmail.org/support/.
You may subscribe/unsubscribe at  https://isid.org/promedmail-subscribe/.
Unsubscribe Preferences ( https://u19268662.ct.sendgrid.net/asm/?user_id=3D=
19268662&data=3DIL5AZ3e2nUe0V0GrkF1ZJfXJGWEPrcSEIGTkhsYS8L9oMDAwdTAwMCgVGvv=
oRuTKGrio-krjm5nUF06-4O68SvTplKfiDVSBQ_w40XRNH9uhmjJh4CM6xczRhIFHgEPb02hwoV=
x2f5mW4T81cbMKTHuefU04DsFS-67fwLeYSCXFvlmWqw5wqrFxdZJTgD_EtxJY2GL1lvYZBAV3P=
ACsiFsUMEf_MniDCgUVpbJmTvw2SqNPytGfNQRVNUwYwOGZVobsHIzSA5V-fH1q6QXDzNeg30T9=
q_e2Refe2pcjjeJ2R-5bBFa2CMMIRp8MW6IN9MqYnHA1tEgzBcoscie5J1rfGcI3xzeosWx0umw=
WB5liZ3yIYYRZ8jxM0ATCM0UXwXgQUoZkhXPhRB7tXofrtMXpJXjw21QGTwN2XUlwzM7sUE-SyZ=
JVOrID-iew0okTXJbzBBTehIm-rbXYWgc8yIVEkSe9alJJtYxB2tGznTmC8MHkBxuoLdaAhV0De=
TbvvcNbW27waw6IHYyzElohljE0KbS9pMpvaOM5p6RCy9mKmYYXAoWzilXQaAPg4x74LjuWUMCf=
zJGtrr7bEWuU4ujQqYn4WSCLUiM0qioPtmX7AcdRffVoLKlHM98PkRHaLJVPRgxfsFMjjtX-VAe=
ygRO2Twv1XnUtnORbBWdQFjPXxok51zZKSlO69dWnhIWJEdQInfROaBRDyZZCloYWHq-IxNUhNN=
fuKGM6Avj7FKtQSB6FeoAnjaRM9BwyqkQRRb2_sCe_NArWoCvgB5BDc8Tr0VurhN0R4zhdu-qze=
l3moYungG_KSjkjpfsvqeFdWCkGx21qIh-u7LfMqkafwBg7PZKKdSIQiDpTjT-97GZWzBAN4qPH=
vVCu05WBqvHpS8ePmYNQLii8plopMxS2EYdhX7mJl4TojwJvC3PtlgXaQRV78pPoYVz-DN4tfuU=
lawTu0YIzFpy_I7pT7ZB-E0X3iLoIQSRLWlkuo4hojW19CLvGF-4m6sDGqjCNXCnTALcoPd823V=
25xrvwBCk_o-6YnZVLprfmiuflBwx6GJFXqJ8KEL1Qc--vUfbDBNLDE2qsPbyCwENFNbXk7QMHt=
tcOAXGQ07eCDRBhqjovT6ZRftySBoNiB9N1XRl6fZkiOuCk3yxi3gUT79iyNmb9NJMrSEPJxE9e=
eqc5-iAW6PvZzlR7n2qxKY5Frg8z57H9p31iWP8ClsAx1iZ0ZX5a9e-Y195hgrz6 )
############################################################
############################################################

--e074754f5a76ce6dcaa5930a94219a84b9d96e28e675a95f2048e4271d85
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset=us-ascii
Mime-Version: 1.0

<!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>MENINGITIS, MENINGOCOCCAL - NIGERIA: UPDATE<br>**********************=
*********************<br>A ProMED-mail post<br><a href=3D"https://u19268662=
.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisIijpefK5PNjW-mL-YZGnfgDOxU1G3gjw=
nPSi2Tfv3HA/430/_go2wTm3T_-xzVOMuJBqmw/h0/IFOdY4bZ6iRf5WyKs87D_TTgBF4-8W95P=
WvicAUX5Ng">http://www.promedmail.org</a><br>ProMED-mail is a program of th=
e<br>International Society for Infectious Diseases<br><a href=3D"https://u1=
9268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisCT5tpD4Upm3qyMCbcYSQvc/43=
0/_go2wTm3T_-xzVOMuJBqmw/h1/LiNdo0aAnAyPqKd9f85CsRX_CLVrocYkVIl_azSM9zw">ht=
tp://www.isid.org</a><br><br>Date: Thu 11 Jan 2024=0D<br>Source: Premium Ti=
mes [edited]=0D<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_cs=
rC34X_iXpbYoMam-Meyahe3DlkX6dr-o43m-oBOQ83rZmFR5FUSW5cfb6XZwEsLEOsu1ri2t0lv=
9E9NnA49EhWXtaIldlgSIHoTQ1BCw0oELajTQ9_VE3svbhXFabmzpgmX02Djmc1dalXUZfsDnRX=
5ypBIXcYdGC_7aY/430/_go2wTm3T_-xzVOMuJBqmw/h2/YmN0lQDNITQroBjiS_wfL2JcItoZo=
Cu8w5FbyDYwNXc">https://www.premiumtimesng.com/news/top-news/657924-meningi=
tis-kills-190-in-nigeria-in-two-years-ncdc.html</a>=0D<br>=0D<br>=0D<br>Bet=
ween 2022 and 2023, Nigeria recorded a total of 303 confirmed cases<br>and =
190 deaths from cerebrospinal meningitis (CSM) across 29 states<br>and the =
Federal Capital Territory (FCT).=0D<br>=0D<br>CSM occurs when there is an a=
cute inflammation of the membranes<br>covering the brain and the spinal cor=
d.=0D<br>=0D<br>According to a public health advisory released Thursday [11=
 Jan 2024]<br>by the Nigeria Centre for Disease Control (NCDC), 2765 suspec=
ted cases<br>of CSM were also recorded across 140 local government areas (L=
GAs) in<br>the affected 29 states and FCT.=0D<br>=0D<br>NCDC noted that the=
 highest burden of CSM in Nigeria occurs in the<br>"Meningitis Belt," which=
 includes all 19 states in the Northern<br>region, the FCT, and some southe=
rn states such as Bayelsa, Cross<br>River, Delta, Ekiti, Ogun, Ondo, and Os=
un.=0D<br>=0D<br>The disease control centre explained that CSM is an epidem=
ic-prone<br>disease with cases reported all year round in Nigeria. It added=
 that<br>weather conditions like the dry season with dust, winds, cold nigh=
ts,<br>and frequent upper respiratory tract infections increase the risk of=
<br>infection.=0D<br>=0D<br>The report shows that the 5-14-year-old age gro=
up was the most<br>affected, and 54% of the total suspected cases were male=
s.=0D<br>=0D<br>Response=0D<br>--------=0D<br>NCDC said it is working to pr=
event, detect, and respond to cases of<br>CSM in collaboration with the Fed=
eral Government of Nigeria through<br>the Federal Ministry of Health and So=
cial Welfare.=0D<br>=0D<br>Despite significant progress in surveillance, di=
agnostic capacity, and<br>vaccination over the last few years, NCDC noted t=
hat CSM remains a<br>priority disease and a public health threat in Nigeria=
 with annual<br>outbreaks in high-burden states.=0D<br>=0D<br>NCDC also hig=
hlighted strategies implemented to ensure enhanced<br>coordination, collabo=
ration, and communication for CSM response in<br>Nigeria in collaboration w=
ith MDAs and partners through the National<br>CSM Technical Working Group (=
TWG).=0D<br>=0D<br>"At the beginning of the season, all state governments a=
nd public<br>health authorities were alerted to the heightened risk of a CS=
M<br>outbreak and the need for resource mobilisation for preparedness and<b=
r>response activities," NCDC noted.=0D<br>=0D<br>It added that they hold ro=
utine meetings of the National<br>Multi-sectoral CSM TWG to coordinate prev=
ention and preparedness<br>activities, and regular communication with high-=
burden states towards<br>ascertaining status, progress, and challenges.=0D<=
br>=0D<br>About meningitis=0D<br>----------------=0D<br>According to NCDC, =
meningitis is an inflammation of the meninges, a<br>thin layer of the conne=
ctive tissue that covers the brain and the<br>spinal cord.=0D<br>=0D<br>Thi=
s inflammation can be caused by infection with organisms like<br>bacteria, =
viruses, parasites, or fungi. Injuries and certain drugs can<br>also cause =
such inflammation.=0D<br>=0D<br>On transmission, NCDC said meningitis is tr=
ansmitted from direct<br>person-to-person contact, including droplets from =
the nose and throat<br>of infected persons, and close and prolonged contact=
 with an infected<br>individual.=0D<br>=0D<br>"CSM initially presents as fe=
ver, headache, nausea and vomiting,<br>photophobia (pain on looking at brig=
ht lights), neck stiffness, and<br>altered conscious levels. It may be more=
 difficult to observe these<br>signs in younger children, but irritability,=
 poor feeding, and<br>inactivity are common," NCDC noted.=0D<br>=0D<br>NCDC=
 advised that people ensure they receive the appropriate<br>vaccination req=
uired to protect against meningitis.=0D<br>=0D<br>[Byline: Mariam Ileyemi]=0D=
<br>=0D<br>--=0D<br>Communicated by:=0D<br>ProMED=0D<br>via=0D<br>ProMED-EA=
FR<br><br>[According to the US CDC, meningococcal disease occurs worldwide,=
 with<br>the highest incidence of disease found in the "meningitis belt" of=
<br>sub-Saharan Africa. In this region, major epidemics occur every 5 to<br=
>12 years with attack rates reaching 1000 cases per 100 000 population.<br>=
The meningitis belt stretches from Senegal to Ethiopia. Most of<br>Northern=
 Nigeria lies within the meningitis belt. Experts opine the<br>reported 190=
 deaths from 2022 to 2023 in Nigeria may be the tip of the<br>iceberg due t=
o poor reporting especially from rural areas and private<br>health faciliti=
es. Vaccination campaigns are key to raising herd<br>immunity and preventin=
g outbreaks of meningococcal meningitis. -<br>Mod.AA=0D<br>=0D<br>ProMED ma=
p of Nigeria:<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/sSnCkKCW=
Bvais3EuVAOvgy2WOIX7pp1nXnn4AbwuQ3Z6WbkfhqXYXU-aTMPJ8yThLBk4Ds6pvCXdDxClbqQ=
7xA/430/_go2wTm3T_-xzVOMuJBqmw/h3/nB9MRlpdfZoNHxew0avXUUGkPYlfn8F5XXqPkUwMm=
7c">https://promedmail.org/promed-post?place=3D8714222,62</a>]<br><br>[See =
Also:<br>2023=0D<br>----=0D<br>Meningitis, meningococcal - Niger (03): fata=
l, Africa CDC<br>http://promedmail.org/post/20230807.8711607=0D<br>Meningit=
is, meningococcal - Niger (02): fatal, sg C, mass vacc, ACW<br>polysac vacc=
 WHO http://promedmail.org/post/20230419.8709577=0D<br>Meningitis, meningoc=
occal - Niger: fatal, sg C, mass vacc., ACW<br>polysac. vacc. WHO http://pr=
omedmail.org/post/20230209.8708257=0D<br>Meningitis - Nigeria: (JI) fatal, =
alert, RFI<br>http://promedmail.org/post/20230125.8707967=0D<br>2022=0D<br>=
----=0D<br>Meningitis, meningococcal - Nigeria: (JI) susp, fatal, children,=
 RFI<br>http://promedmail.org/post/20220611.8703809=0D<br>2019=0D<br>----=0D=
<br>Meningitis, meningococcal - Niger (02): counterfeit vaccines, alert<br>=
http://promedmail.org/post/20190401.6398266=0D<br>Meningitis, meningococcal=
 - Niger: counterfeit vaccine<br>http://promedmail.org/post/20190317.637200=
3=0D<br>2017=0D<br>----=0D<br>Meningitis, meningococcal - Niger: fatal<br>h=
ttp://promedmail.org/post/20170519.5048548=0D<br>2016=0D<br>----=0D<br>Meni=
ngitis, meningococcal - Niger: fatal<br>http://promedmail.org/post/20160331=
.4130594=0D<br>2015=0D<br>----=0D<br>Meningitis, meningococcal - Niger (05)=
: serogroup C, fatal, vaccine<br>shortage http://promedmail.org/post/201508=
02.3552463=0D<br>Meningitis, meningococcal - Niger (04): serogroup C, fatal=
, WHO,<br>update http://promedmail.org/post/20150724.3533998=0D<br>Meningit=
is, meningococcal - Niger (03): serogroup C, fatal, WHO,<br>update http://p=
romedmail.org/post/20150517.3368315=0D<br>Meningitis, meningococcal - Niger=
 (02): fatal, update<br>http://promedmail.org/post/20150506.3344024=0D<br>M=
eningitis, meningococcal - Niger: fatal, serogroups C, W<br>http://promedma=
il.org/post/20150430.3332448]<br>..........................................=
.......aa/may/ya/tw/jh<br></body>
</html><!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>*##########################################################*<br>*****=
*******************************************************<br>ProMED makes eve=
ry effort to verify the reports that are posted, but the accuracy<br>and co=
mpleteness of the information, and of any statements or opinions based<br>t=
hereon, are not guaranteed. The reader assumes all risks in using informati=
on<br>posted or archived by ProMED. ISID and its associated service provide=
rs shall not<br>be held responsible for errors or omissions or held liable =
for any damages incurred<br>as a result of use or reliance upon posted or a=
rchived material.<br>******************************************************=
******<br>Donate to ProMED. Details available at: https://isid.networkforgo=
od.com/projects/79924-invest-in-the-mission.<br>***************************=
*********************************<br>Visit ProMED's website at https://www.=
promedmail.org/.<br>Submit all items for posting via the ProMED website at =
https://promedmail.org/submitinfo/.<br>If you have any questions or need su=
pport, please contact us via the ProMED website at  https://promedmail.org/=
support/.<br>You may subscribe/unsubscribe at  https://isid.org/promedmail-=
subscribe/.<br><div><a href=3D"https://u19268662.ct.sendgrid.net/asm/?user_=
id=3D19268662&amp;data=3DIL5AZ3e2nUe0V0GrkF1ZJfXJGWEPrcSEIGTkhsYS8L9oMDAwdT=
AwMCgVGvvoRuTKGrio-krjm5nUF06-4O68SvTplKfiDVSBQ_w40XRNH9uhmjJh4CM6xczRhIFHg=
EPb02hwoVx2f5mW4T81cbMKTHuefU04DsFS-67fwLeYSCXFvlmWqw5wqrFxdZJTgD_EtxJY2GL1=
lvYZBAV3PACsiFsUMEf_MniDCgUVpbJmTvw2SqNPytGfNQRVNUwYwOGZVobsHIzSA5V-fH1q6QX=
DzNeg30T9q_e2Refe2pcjjeJ2R-5bBFa2CMMIRp8MW6IN9MqYnHA1tEgzBcoscie5J1rfGcI3xz=
eosWx0umwWB5liZ3yIYYRZ8jxM0ATCM0UXwXgQUoZkhXPhRB7tXofrtMXpJXjw21QGTwN2XUlwz=
M7sUE-SyZJVOrID-iew0okTXJbzBBTehIm-rbXYWgc8yIVEkSe9alJJtYxB2tGznTmC8MHkBxuo=
LdaAhV0DeTbvvcNbW27waw6IHYyzElohljE0KbS9pMpvaOM5p6RCy9mKmYYXAoWzilXQaAPg4x7=
4LjuWUMCfzJGtrr7bEWuU4ujQqYn4WSCLUiM0qioPtmX7AcdRffVoLKlHM98PkRHaLJVPRgxfsF=
MjjtX-VAeygRO2Twv1XnUtnORbBWdQFjPXxok51zZKSlO69dWnhIWJEdQInfROaBRDyZZCloYWH=
q-IxNUhNNfuKGM6Avj7FKtQSB6FeoAnjaRM9BwyqkQRRb2_sCe_NArWoCvgB5BDc8Tr0VurhN0R=
4zhdu-qzel3moYungG_KSjkjpfsvqeFdWCkGx21qIh-u7LfMqkafwBg7PZKKdSIQiDpTjT-97GZ=
WzBAN4qPHvVCu05WBqvHpS8ePmYNQLii8plopMxS2EYdhX7mJl4TojwJvC3PtlgXaQRV78pPoYV=
z-DN4tfuUlawTu0YIzFpy_I7pT7ZB-E0X3iLoIQSRLWlkuo4hojW19CLvGF-4m6sDGqjCNXCnTA=
LcoPd823V25xrvwBCk_o-6YnZVLprfmiuflBwx6GJFXqJ8KEL1Qc--vUfbDBNLDE2qsPbyCwENF=
NbXk7QMHttcOAXGQ07eCDRBhqjovT6ZRftySBoNiB9N1XRl6fZkiOuCk3yxi3gUT79iyNmb9NJM=
rSEPJxE9eeqc5-iAW6PvZzlR7n2qxKY5Frg8z57H9p31iWP8ClsAx1iZ0ZX5a9e-Y195hgrz6" =
target=3D"_blank" class=3D"Unsubscribe--unsubscribePreferences" style=3D"fo=
nt-family:sans-serif;text-decoration:none;">Unsubscribe Preferences</a></di=
v><br>############################################################<br>#####=
#######################################################<br><br><img src=3D"=
https://u19268662.ct.sendgrid.net/ss/o/LbtalBvHhFtzyiegKfBhew/430/_go2wTm3T=
_-xzVOMuJBqmw/ho.gif" alt=3D"" width=3D"1" height=3D"1" border=3D"0" style=
=3D"height:1px !important;width:1px !important;border-width:0 !important;ma=
rgin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;=
margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !importa=
nt;padding-right:0 !important;padding-left:0 !important;"/></body>
</html>
--e074754f5a76ce6dcaa5930a94219a84b9d96e28e675a95f2048e4271d85--
